BioRestorative Therapies (BioRestorative Therapies) EBIT per Share : $-3.71 (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is BioRestorative Therapies EBIT per Share?

BioRestorative Therapies's EBIT per Share for the three months ended in Dec. 2023 was $-0.69. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.71.

During the past 3 years, the average EBIT per Share Growth Rate was 2.30% per year. During the past 5 years, the average EBIT per Share Growth Rate was 71.90% per year. During the past 10 years, the average EBIT per Share Growth Rate was 63.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for BioRestorative Therapies's EBIT per Share or its related term are showing as below:

BRTX' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -129.5 Med: 41.1 Max: 90.3
Current: 2.3

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of BioRestorative Therapies was 90.30% per year. The lowest was -129.50% per year. And the median was 41.10% per year.

BRTX's 3-Year EBIT Growth Rate is ranked worse than
51.95% of 1305 companies
in the Biotechnology industry
Industry Median: 3.6 vs BRTX: 2.30

BioRestorative Therapies's EBIT for the three months ended in Dec. 2023 was $-3.22 Mil.

BioRestorative Therapies EBIT per Share Historical Data

The historical data trend for BioRestorative Therapies's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioRestorative Therapies EBIT per Share Chart

BioRestorative Therapies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-500.47

-13.45

-22.15

-5.21

-3.59

BioRestorative Therapies Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT per Share	Get a 7-Day Free Trial															-1.25	-1.56	-0.80	-0.66	-0.69

BioRestorative Therapies EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

BioRestorative Therapies's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-15.137	/	4.218
=	-3.59

BioRestorative Therapies's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-3.221	/	4.687
=	-0.69

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.71

BioRestorative Therapies (NAS:BRTX) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

BioRestorative Therapies EBIT per Share Related Terms

Thank you for viewing the detailed overview of BioRestorative Therapies's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

BioRestorative Therapies (BioRestorative Therapies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioRestorative Therapies Inc (NAS:BRTX) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

9OF:Germany

Address

40 Marcus Drive, Suite One, Melville, NY, USA, 11747

Website

https://www.biorestorative.com

BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.

Executives

Dale Broadrick	10 percent owner	3003 BRICK CHURCH PIKE, NASHVILLE TN 37207
Lance Alstodt	director, 10 percent owner, officer: President, CEO, COB	BIORESTORATIVE THERAPIES, INC., 40 MARCUS DRIVE, SUITE 1, MELVILLE NY 11747
Francisco Silva	director, 10 percent owner, officer: VP of Research and Development	STEM CELL ASSURANCE, INC., 555 HERITAGE DRIVE, JUPITER FL 33458
Robert Eugene Kristal	officer: Chief Financial Officer	4719 COLE AVENUE, DALLAS TX 75205
Patrick F. Williams	director	C/O ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD, SUITE 100, PLEASANTON CA 94588
David A Rosa	director	10901 RED CIRCLE DRIVE, SUITE 150, MINNETONKA MN 55343
Nickolay V. Kukekov	director	4524 WESTWAY AVE, DALLAS TX 75205
Mark Weinreb	director, 10 percent owner, officer: CEO and Chairman of the Board	STEM CELL ASSURANCE, INC., 555 HERITAGE DRIVE, JUPITER FL 33458
Paul Jude Tonna	director	69 CHICHESTER ROAD, HUNTINGTON NY 11743
A. Jeffrey Radov	director	8 WALWORTH AVENUE, SCARSDALE NY 10583
Robert Paccasassi	officer: VP, Quality and Compliance	C/O BIORESTORATIVE THERAPIES, INC., 40 MARCUS DRIVE, SUITE 1, MELVILLE NY 11747
Robert B Catell	director	62 OSBORNE ROAD, GARDEN CITY NY 11530
Adam D. Bergstein	officer: SVP, Planning and Business Dev	167 HAZEL AVENUE, GLENCOE IL 60022
John M Desmarais	director	230 PARK AVENUE, NEW YORK NY 10169
Westbury Trust	10 percent owner	VICTORIA HALL, 11 VICTORIA STREET, P.O. BOX HM 1065, HAMILTON D0 00000